1. Introduction {#s0010}
===============

The giant panda, *Ailuropoda melanoleuca*, is one of the world\'s most recognised and rarest animals. It is a solitary bear of the subfamily Ailuropodinae in the family Ursidae, whose diet is mainly bamboo ([@bb0375]). Giant pandas usually live for 14--20 years in the wild and up to 38 years in captivity (China Conservation and Research Centre for the Giant Panda, CCRCGP, unpublished data; [@bb0350]). From the 16th to the 19th centuries, this panda was distributed widely in Western China (Gansu, Hubei, Hunan, Shaanxi and Sichuan provinces; [@bb0685]). However, today, this species is restricted to 30--40 populations in six isolated mountain ranges at the eastern edge of the Tibetan plateau in China, i.e., the Minshan, Qionglai, Qinling, Daxiangling, Xiaoxiangling and Liangshan mountains ([Fig. 1](#f0010){ref-type="fig"} ), with a total estimated population size of 1864 in the wild ([@bb0385]). To protect this iconic and threatened animal, more than 375 giant pandas have been raised in captivity in conservation centres and zoos ([@bb0385]).Fig. 1Distribution of wild giant pandas in six mountain regions (Qinling, Minshan, Qionglai, Liangshan, Daxiangling and Xiaoxiangling) in China.Fig. 1Adapted from Zhang, L., Wu, Q., Hu, Y., Wu, H., Wei, F., 2015. Major histocompatibility complex alleles associated with parasite susceptibility in wild giant pandas. Heredity (Edinb) 114, 85--93.

Many factors threaten this endangered species, including habitat loss, degradation and fragmentation, poor reproduction and limited resistance to some infectious diseases ([@bb0060]; [@bb0505]; cf. [Tables 1](#t0010){ref-type="table"} and [2](#t0015){ref-type="table"} ). Of these factors, diseases caused by parasites are reported to be a major threat to the conservation of the giant panda. In particular, a disease (baylisascariasis) caused by the ascaridoid nematode *Baylisascaris schroederi* ([@bb0275]) is a leading cause of deaths in wild populations ([@bb0630]). Indeed, between 2001 and 2005, visceral larva migrans (VLM) linked to *B. schroederi* infection was reported to be responsible for 50% (12/24) of mortalities in the giant panda ([@bb0630]).Table 1Viruses and Bacteria Which Have the Potential to Threaten the Health and Conservation of the Giant PandaTable 1PathogensClassificationLocationSigns or ProblemCommentsReferences*Viruses*Canine distemper virusParamyxoviridaeNervous, digestive and respiratory systemsFever and inflammationThe most dangerous virus to the giant pandas[@bb0110] and [@bb0665]Canine adenovirusAdenoviridaeLiver and brain[@bb0305]Canine coronavirusCoronaviridaeStomach and intestineMental depression, vomiting, flatulence and watery diarrhoeaThere is no comprehensive knowledge on CCV of giant pandas[@bb0250]Canine parvovirusParvoviridaeUnknownWatery diarrhoea and vomiting[@bb0250] and [@bb0305]RotavirusReoviridaeStomach and small intestineDepression, anorexia vomiting and diarrhoea[@bb0470]*BacteriaClostridium perfringens* (*Clostridium welchii*)BacillaceaeIntestineSubclinicalOpportunistic pathogen; sudden death[@bb0290]*Escherichia coli*EnterobacteriaceaeIntestinal tract and vaginaDiarrhoea, hemorrhagic enterocolitis and intestinal mucosal inflammationOpportunistic pathogen[@bb0490]*Klebsiella pneumoniae*EnterobacteriaceaeRespiratory and intestinal tractsLethargy, mental depression, diarrhoea, inappetence, emaciation vomiting, haematochezia and haemorrhagic enterocolitis[@bb0585]*Proteus mirabilis*EnterobacteriaceaeUrogenital tractUrinary urogenital infectionsOpportunistic pathogen; might cause reproductive problems in females[@bb0460]Table 2Parasites Recorded in the Giant PandaTable 2ParasiteClassificationLocationFirst ReportComplicationsCommentsReferences*HelminthsAncylostoma ailuropodae* sp. nov.AncylostomatidaeSmall intestineFirst reported as *Ancylostoma caninum* in Sichuan province, China (2005). Renamed as *Ancylostoma ailuropodae*, based on morphological study ([@bb0555])n/aValidity needs to be confirmed[@bb0160] and [@bb0555]*Baylisascaris schroederi* sp. nov.AscarididaeSmall intestineFirst reported in the Bronx Zoo, USA (1939)Intestinal obstruction, emaciation, inflammation (enteritis and pneumonia), sometimes deathThe most studied parasite of the giant panda[@bb0275] and [@bb0365]Lungwormn/an/aFirst reported in Sichuan province, China (1991)n/aNo genus and species names\
Identification based on egg examination[@bb0160]*Strongyloides* sp.StrongyloididaeSmall intestineFirst reported in Sichuan province, China (1991)n/aIdentification based on egg examination. Parasite name misspelled as '*Storonglata*'[@bb0160]*Toxascaris seleactis*AscarididaeSmall intestineFirst reported in Sichuan province, China (1991)n/aIdentification based on egg examination[@bb0160]*Ogmocotyle sikae*NotocotylidaeSmall intestineFirst reported from an informal publication by [@bb0085] in Shanxi province, China (without morphological description)n/aLife cycle and pathogenesis unknown[@bb0085] and [@bb0360]First detailed morphological and phylogenetic studies conducted by [@bb0360]*ProtistsCryptosporidium* sp.CryptosporidiidaeGastrointestinal tractFirst reported with a prevalence of 1.75% (1/57) in Sichuan province, China (2013), with morphological and phylogenetic analysisNo associated clinical signsPotential novel genotype[@bb0230]*Cryptosporidium andersoni*CryptosporidiidaeGastrointestinal tractFirst reported with a prevalence of 15.6% (19/122) and 0.5% (1/200) in captive and wild giant pandas, Sichuan province, China (2015)No associated clinical signs[@bb0495]*Enterocytozoon bieneusi*MicrosporidiaSmall intestineFirst reported with a prevalence of 8.70% (4/46) in the northwest of China (2015)No associated clinical signsPotential novel genotype[@bb0390]*Toxoplasma gondii*SarcocystidaeLiver, spleen, lungs, kidneys and intestinesFirst reported in a dead captive panda in Henan province, China (2015)Fatal toxoplasmosis associated with serious respiratory and gastroenteritis signsPotential novel genotype[@bb0245]*Sarcocystis* sp.SarcocystidaeMuscleDescribed in two reviews of parasites of the giant panda ([@bb0690], [@bb0695]); however, original literature is not available from either reviewn/an/a*Ectoparasites*BlowflyUnknownThe gastroenteritis maggots were found in a giant panda (2007), without morphological descriptionn/aNo genus and species names[@bb0195]*Dermacentor taiwanensis*IxodidaeSkin surfaceDescribed in two reviews of parasites of the giant panda ([@bb0690], [@bb0695]); however, original literature is not available from either reviewn/an/a*Haemaphysalis aponommoides*IxodidaeSkin surfaceFirst reported in Sichuan province, China (1985)n/a[@bb0155]*H. flava*IxodidaeSkin surfaceFirst reported in Sichuan province, China (1990) without morphological description; first detailed morphological and phylogenetic analysis were conducted by [@bb0030]n/a[@bb0030] and [@bb0155]*H. hystricis*IxodidaeSkin surfaceDescribed in two reviews of parasites of the giant panda ([@bb0690], [@bb0695]); however, original literature is not available from either reviewn/an/a*H. kitaotai*IxodidaeSkin surfaceDescribed in two reviews of parasites of the giant panda ([@bb0690], [@bb0695]); however, original literature is not available from either reviewn/an/a*H. longicornis*IxodidaeSkin surfaceFirst reported in Sichuan province, China (1992) with detailed morphological descriptionn/a[@bb0025]*H. megaspinosa*IxodidaeSkin surfaceFirst reported in Gansu province, China (1987) without morphological descriptionn/a[@bb0240]*H. montgomeryi*IxodidaeSkin surfaceFirst reported in Gansu province, China (1987) without morphological descriptionn/a[@bb0240]*H. warburtoni*IxodidaeSkin surfaceFirst reported in Sichuan province, China (1985) with detailed morphological descriptionn/a[@bb0510]*H. ailuropodae* sp. nov.IxodidaeSkin surfaceFirst reported in Shanxi province, China (1998) with detailed morphological description; no associated clinical signs reportedn/aValidity needs to be confirmed[@bb0610]*Ixodes acutitarsus*IxodidaeSkin surfaceFirst reported in Gansu province, China (1987) without morphological descriptionn/a[@bb0240]*I. granulatus*IxodidaeSkin surfaceFirst reported in Gansu province, China (1987) without morphological descriptionn/a[@bb0240]*I. ovatux*IxodidaeSkin surfaceFirst reported in Gansu province, China (1987) without morphological descriptionn/a[@bb0240]*Chorioptes panda* sp. nov.PsoroptidaeSkin surfaceFirst reported in Paris Zoo, France (1975)Mild alopecia, erythema and crusting affecting sleep and appetite[@bb0055]*Chaetopsylla ailuropodae*VermipsyllidaeSkin surfaceFirst reported in Sichuan province, China (1991) with detailed morphological descriptionn/a[@bb0330]*C. mikado*VermipsyllidaeSkin surfaceFirst reported in Sichuan province, China (1990) with detailed morphological descriptionn/a[@bb0155]*Demodex ailuropodae*DemodicidaeHair follicles, sebaceous glandFirst reported in Shanghai, China (1985), with detailed morphological descriptionn/a[@bb0565][^1]

However, surprisingly, there is limited published information on the parasites of the giant panda (*n*  = 91 peer-reviewed publications and archived governmental reports; 14 January 2017 ), most of which have been published in the Chinese literature (*n*  = 55 publications). Unpublished information from zoos, animal parks and breeding centres (sources available from authors) suggests that parasites of the giant panda continue to be a persistent and chronic issue, adversely impacting the health and conservation of this iconic animal. Therefore, we consider it appropriate and timely to review the literature on parasites of the giant panda, with an emphasis on *B. schroederi* because it dominates published literature. The purpose of this chapter is to: (i) review the parasites recorded in the giant panda and describe what is known about their life cycles; (ii) discuss key aspects of the pathogenesis, diagnosis, treatment and control of common parasites and (iii) conclude by making some suggestions for future research.

2. Parasite Records for the Giant Panda {#s0015}
=======================================

Since *B. schroederi* (originally named *Ascaris schroederi*) ([@bb0275]) was found in the small intestine from a giant panda in the New York Zoological Park (now the Bronx Zoo) in 1939, an increasing number of parasites have been identified in this animal species. To date, at least 29 parasite taxa, including 11 endoparasites (5 nematode, 1 trematode and 5 protozoan taxa) and 18 ectoparasites (13 tick, 2 mite, 2 flea taxa and 1 'blow fly') have been recorded in the giant panda ([Table 2](#t0015){ref-type="table"}). However, many of these records are in the Chinese literature (publications or archival documents), often with very limited descriptions of morphology and/or other aspects. Beyond these records, reports of clinical cases often involve *B. schroederi*, the mite *Chorioptes panda* and ixodid ticks.

2.1. Key Parasites Reported to Cause Clinical Problems {#s0020}
------------------------------------------------------

### 2.1.1. Baylisascaris schroederi {#s0025}

*B. schroederi* (Nematoda: Ascaridoidea) is a large parasitic nematode inhabiting the small intestine of giant pandas and belongs to the genus *Baylisascaris*, of which there are 11 species, namely, *B. procyonis* of raccoons, *B. columnaris* of skunks, *B. potosis* of kinkajous, *B. ailuri* of red pandas, *B. transfuga* of bears, *B. melis* of badgers, *B. laevis* of marmots and ground squirrels, *B. devosi* of marten and fishers, *B. tasmaniensis* of Tasmanian devils and quolls and *B. venezuelensis* of spectacled bears ([@bb0135]; [@bb0300]; [@bb0365]; [@bb0395]; [@bb0400]; [Table 3](#t0020){ref-type="table"} ). There is no evidence that *B. schroederi* affects other animal species or humans under natural conditions. Despite its massive health impact on wild giant panda populations in the early 20th century ([@bb0315]; [@bb0630]), *B. schroederi* was first described in 1939 as *Ascaris schroederi* ([@bb0275]), before being renamed *B. schroederi* in 1968 ([@bb0365]). Presently, baylisascariasis is considered the most harmful parasitic disease of the giant panda ([@bb0060]; [@bb0645]). Thus, *B. schroederi* has been the most studied parasite of this animal. Most published studies have investigated important aspects of this parasite\'s biology, epidemiology, pathogenesis, diagnosis, treatment and control.Table 3Recognized Species of *Baylisascaris*Table 3Species[a](#tf0010){ref-type="table-fn"}Primary Definitive Host(s)[b](#tf0015){ref-type="table-fn"}*Baylisascaris ailuri* (Wu et al., 1987)Red panda*Baylisascaris columnaris* (Leidy, 1856)Skunks*Baylisascaris devosi* (Sprent, 1952)Marten, fisher*Baylisascaris melis* (Gedoelst, 1920)European badger*Baylisascaris potosis* ([@bb0395])Kinkajou*Baylisascaris procyonis* (Stefanski and Zarnowski, 1951)Raccoon*Baylisascaris schroederi* ([@bb0275])Giant panda*Baylisascaris transfuga* (Rudolphi, 1819)Bears*Baylisascaris laevis* (Leidy, 1856)Ground hog, ground squirrels*Baylisascaris tasmaniensis* (Sprent, 1970)Tasmanian devil, quolls*Baylisascaris venezuelensis* ([@bb0300])Spectacled bear[^2][^3]

#### 2.1.1.1. Life Cycle {#s0030}

Similar to many other ascaridoids, *B. schroederi* has a complex life cycle in a single host, involving larval moults and development in several organ systems. Although not all aspects of this cycle have been proven, based on postmortem findings for giant pandas (CCRCGP, unpublished data) and experimentally infection studies in mice ([@bb0170], [@bb0175], [@bb0180], [@bb0185]), evidence indicates that giant pandas become infected via the faecal--oral route, and larvae undergo hepatopulmonary and somatic migration prior to establishing as dioecious adults in the small intestine. Currently, there is no evidence of vertical or transmammary transmission of *B. schroederi*.

The current understanding is that, after eggs hatch in the intestine, the infective larvae penetrate the mucosa of the intestine. Subsequently, based on current knowledge, the larvae migrate via the mesenteric and portal blood system to the liver and then the lungs, and eventually return (via the trachea) to the intestinal lumen, where they mature to adults, mate and reproduce. Unembryonated eggs are released from female worms into chyme and faeces into the environment, where they can remain viable in moist soil for many years ([@bb0105]; [@bb0165]; [@bb0575]). Previous studies have shown that eggs of *B. schroederi* survive better than those of some other ascaridoids, such as *Ascaris lumbricoides* and *Ascaris suum*, and are characterised by rapid embryonation and resistance to low temperatures (4--12°C) ([@bb0165]; [@bb0515]). It usually takes 2--4 weeks for fertile eggs of *B. schroederi* to become infective at 22°C in moist and shaded soil ([@bb0525]), whereas 6--10 weeks are required by *Ascaris* eggs under the same conditions ([@bb0270]). [@bb0165] found that 43% of *B. schroederi* eggs contained infective larvae within 30 days at − 10°C.

#### 2.1.1.2. Epidemiology {#s0035}

Since *Baylisascaris* eggs are highly resistant to environmental pressures (e.g. temperature and desiccation), it is difficult for panda individuals to avoid exposure once the environment is contaminated ([@bb0620]). According to the limited, but valuable reports on the prevalence of *B. schroederi* infection ([@bb0060]; [@bb0160]; [@bb0210]; [@bb0295]; [@bb0455], [@bb0485]; [@bb0570]; [@bb0595]; [@bb0610]; [@bb0635], [@bb0645]; [@bb0680]), baylisascariasis commonly occurs in wild and captive populations of the giant panda ([@bb0235]). It is noteworthy that *B. schroederi* infection has been frequently detected in giant pandas upon arrival at international zoos, such as Adelaide Zoo (Australia), Chiang Mai Zoo (Thailand), Edinburgh Zoo (UK), Kebecity Oji Zoo (Japan), Pairi Daiza Zoo (Belgium), San Diego Zoo (USA), Smithsonian National Zoo (USA), Ueno Zoo (Japan) and Zoo Negara (Malaysia) (personal communication, Chengdong Wang, 10 February 2017).

[Table 4](#t0025){ref-type="table"} shows up-to-date, published prevalence information for *B. schroederi* infection in giant pandas (in English or Chinese language). Although there are questions surrounding the validity of some information in some Chinese publications, due to incomplete descriptions of methodologies and/or result sections, it is reassuring to see that independent studies, applying different methodologies, reveal similar findings, namely (1) that *B. schroederi* infection is commonly found in the wild giant panda populations across all six isolated mountain ranges in China ([Fig. 1](#f0010){ref-type="fig"}), (2) that the prevalence of infection in captive giant pandas is high (7%--88%) in most of breeding centres and zoos, (3) that the infection rate has not changed significantly over the last four decades in both captive and wild populations and (4) that there is no significant difference in the prevalence of *B. schroederi* infection among different age groups of giant pandas or between the sexes from previous large-scale surveys (*n*  = 2680, [@bb0160]; *n*  = 336, [@bb0570]). In this context, it is noteworthy to mention that [@bb0635] employed a genetic testing technique to link each stool sample to individual wild giant pandas, when estimating the prevalence of *B. schroederi* infection. The use of this noninvasive, genetic approach simultaneously provides the precise number of individual pandas sampled as well as the *B. schroederi* infection status ([@bb0635]).Table 4Published Prevalence Information for *Baylisascaris schroederi* of the Giant PandaTable 4YearLocation[a](#tf0020){ref-type="table-fn"}PopulationTechnique[b](#tf0025){ref-type="table-fn"}Reported PrevalenceReferences1974--1986Minshan and QionglaiWildn/a100% (50/50)[@bb0595]1984Shanghai ZooCaptiveSedimentation--flotation technique67% (2/3)[@bb0295]1985Minshan and QionglaiWildNecropsy100% (13/13)[@bb0060]1985--1988Minshan, Qionglai, Daxiangling, Xiaoxiangling and LiangshanWildSedimentation--flotation technique56% (1050/2680)[@bb0160]1985--1988MinshanWildSedimentation--flotation technique78% (262/336)[@bb0570]Qionglai83% (160/194)Liangshan60% (81/135)Daxiangling and Xiaoxiangling47% (15/32)1998Qinling mountainWildSedimentation--flotation technique100% (2/2)[@bb0610]2001Chengdu ZooCaptiveSedimentation--flotation technique7% (1/14)[@bb0455]2006--2008QinlingWildSedimentation--flotation technique66% (31/47)[@bb0635]Minshan44% (10/23)Qionglai48% (14/29)Liangshan57% (8/14)Daxiangling80% (4/5)Xiaoxiangling13% (1/8)2009--2010MinshanWildPCR/CE-SSCP48% (15/31)[@bb0640]2012Ya'an, CCRCGPCaptivePCR (*cox*2)68% (34/50)[@bb0485]2013Ya'an, CCRCGPCaptivePCR (12S rRNA)88% (44/50)[@bb0680]2014Ya'an, CCRCGP and Chengdu, CRBGPCaptiveSedimentation--flotation technique26% (54/210)[@bb0210]2014Minshan, Qionglai, Qinling, Xiaoxiangling and LiangshanWildMcMaster method55% (48/87)[@bb0645][^4][^5]

#### 2.1.1.3. The Disease: Baylisascariasis {#s0040}

Most pathological and clinical features of baylisascariasis in the giant panda are caused by the migration of *B. schroederi* larvae in various tissues and by adult worms in the gastrointestinal tract ([@bb0060]; [@bb0595]). When the *Baylisascaris* larvae migrate through the tissues of their host, significant tissue damage relates predominantly to extensive inflammation and (subsequent) scarring in the intestinal wall as well as in the parenchymata of the liver and lungs ([@bb0175], [@bb0180]; [@bb0235]). In some extreme cases, in addition to inflammation, entangled or clumped adult worms can lead to mechanical intestinal obstruction, which can be life-threatening ([Fig. 2](#f0015){ref-type="fig"}A) ([@bb0180]; [@bb0465]). Moreover, although not yet reported, it is possible that pulmonary injury caused by migrating *Baylisascaris* larvae may enable or exacerbate bacterial infections (cf. [@bb0575]). To date, there have been no reports of neural larva migrans associated with *B. schroederi* as seen for *B. procyonis* in raccoons (*Procyon lotor*) in North America ([@bb0080]; [@bb0140]).Fig. 2Selected parasites of the giant panda. (A) The parasitic nematode *Baylisascaris schroederi* in the gastrointestinal tract of the giant panda, causing obstruction. (B) *Baylisascaris schroederi* expelled from an infected giant panda following anthelmintic treatment. (C) The mite *Chorioptes panda* and its typical predilections sites on the eyelid and/or lips (D). *Red arrows* indicating *B. schroederi* (B) or skin affected by *C. panda* (C and D).Fig. 2

Morbidity and mortality associated with baylisascariasis are reported to relate directly to the intensity of *B. schroederi* infection ([@bb0315]), whereas individual pandas harbouring small numbers of worms tend to be asymptomatic. In captive giant panda populations, where there is a focus on controlling *B. schroederi*, this nematode rarely causes specific clinical symptoms (CCRCGP, unpublished clinical records), although the migration of larvae through lungs can cause acute symptoms, such as coughing and wheezing, particularly in young cubs ([@bb0575]). Nonetheless, it is commonly observed that captive giant pandas, especially juveniles, can pass whole adult worms in the faeces or vomit (CCRCGP, unpublished data; [@bb0235]). Nevertheless, *B. schroederi* infection is presently recognised as the biggest threat to free-ranging panda populations ([@bb0315]). Based on the literature (including publications in Chinese scientific journals, governmental reports and websites) between 1971 and 2005, [@bb0630] studied the causes of death in 789 adult wild giant pandas in natural habitats. These authors concluded that VLM caused by *B. schroederi* appeared to be the most significant threat of the three major factors of wild giant panda mortality during that period, the other two factors being food shortage (i.e. flowering and 'die-off' of bamboo; [@bb0335]) and poaching ([@bb0190]). Surprisingly, baylisascariasis was reported to be responsible for 50% (12/24) of all deaths in free-ranging giant pandas between 2001 and 2005 ([@bb0630]).

#### 2.1.1.4. Diagnosis {#s0045}

Although the presence of adult worms in the faeces or vomit indicates infection in giant pandas, the diagnosis of *B. schroederi* infection is commonly performed using the quantitative McMaster test or a semiquantitative sedimentation--flotation method in most breeding centres and zoos ([@bb0235]; [@bb0625]). However, due to the large amount of undigested bamboo fibers in giant panda\'s faeces, *B. schroederi* eggs may be challenging to detect using a microscopy upon routine laboratory examination. In some instances, giant pandas with repeatedly 'negative' faecal test results have been reported to suddenly vomit bundles of worms. Hence, test sensitivity appears to be relatively low, in spite of the high reproductive index of *B. schroederi* (see [@bb0575]), suggesting that 'false negative' results might relate to the presence of immature worms in the intestines.

Polymerase chain reaction (PCR)-based techniques can overcome this issue. For instance, some researchers ([@bb0485]; [@bb0680]) have developed a PCR-based tool to directly amplify parts of the mitochondrial 12S ribosomal RNA or cytochrome *c* oxidase subunit 2 (*cox*2) gene from stool DNA samples. Their results showed that this tool is able to detect genomic DNA amounts that are at least equivalent to that from a single egg of *B. schroederi* and are more sensitive (0.5--1 time) than traditional coproscopic methods. In addition, no 'cross-reactivity' with DNA from other nematodes (i.e. *Ancylostoma caninum*, *B. transfuga* or *B. procyonis*) was found using this molecular diagnostic approach. In addition, other workers ([@bb0640]) employed a combined PCR and capillary electrophoretic-based single-strand conformation polymorphism analysis (PCR-based CE-SSCP) using the mitochondrial gene *cox*2 to screen for *B. schroederi* DNA in stool samples from wild giant pandas from the Minshan mountains. Using this approach, these authors concluded that they were able to establish the prevalence and intensity of *B. schroederi* infection.

Apart from conventional and molecular tests, some progress has been made on developing serological detection methods. For instance, an antibody detection enzyme-linked immunosorbent assay (ELISA) employing a *B. schroederi* glutathione *S*-transferase antigen was established for the detection anti-*B. schroederi* serum antibody (IgG) in experimentally infected mice, with a sensitivity of 79.1% and a specificity of 82.0% ([@bb0545]). However, such an assay has not yet been assessed for the diagnosis of baylisascariasis or *B. schroederi* infection in giant pandas. In the meantime, preliminary experiments are being planned at Ghent University (Belgium) and CCRCGP to assess an ELISA using *A. suum* antigen ([@bb0440]) for the serological monitoring of *B. schroederi* infection in pandas.

#### 2.1.1.5. Treatment and Control {#s0050}

The transmission of *B. schroederi* infection within and among captive giant panda populations is dependent on various factors, including the housing system, hygiene, management practices and anthelmintic treatment. However, to accomplish the short-term goal of reducing infection intensity and transmission potential, current control strategies rely mainly on monthly coprological examination (for eggs) and a mass anthelmintic treatment strategy (all individuals, including those with possible false-negative results for *B. schroederi*) ([@bb0235]; [@bb0520]). Anthelmintics used in practice include pyrantel pamoate; albendazole, fenbendazole, mebendazole; ivermectin, milbemycin oxime, doramectin and selamectin (CCRCGP, unpublished data; [@bb0235])---the dosages of these compounds are indicated in [Table 5](#t0030){ref-type="table"} . Usually, multiple (2--4) treatments are given until an individual panda ceases to expel worms and/or eggs in the faeces ([Fig. 2](#f0015){ref-type="fig"}B) ([@bb0520]; CCRCGP, unpublished clinical records; for limitations of conventional diagnostic methods, see [Section 2.1.1.4](#s0045){ref-type="sec"}). However, the efficacies of these anthelmintics at the doses routinely used against *B. schroederi* have not yet been critically assessed in captive giant pandas. Thus, there is a need to evaluate and compare the efficacies of these anthelmintics using a standardised protocol (cf. International Harmonisation of Anthelmintic Efficacy Guidelines; [@bb0425], [@bb0430]).Table 5Suggested Efficacy of Different Anthelmintic Drugs Tested Against *Baylisascaris schroederi*Table 5AnthelminticsFormulationDosageEffect[b](#tf0035){ref-type="table-fn"}References[c](#tf0040){ref-type="table-fn"}Albendazole[a](#tf0030){ref-type="table-fn"}Oral6 mg/kg, onceNegative of eggs in faecal floatation examination after 9 days of treatment[@bb0225]Doramectin[a](#tf0030){ref-type="table-fn"}Pour on0.5 mg/kg, oncen/aCCRCGP (unpublished data)FebantelOral20 mg/kg, onceReported as effective without supporting data[@bb0515]Fenbendazole[a](#tf0030){ref-type="table-fn"}Oral5 mg/kg, oncen/aCCRCGP (unpublished data)LevamisoleOral7--8 mg/kg per 2 months, four timesNegative of worm or eggs in faecal examination after four times of treatment[@bb0520]Oral/in feed5--10 mg/kg, onceNegative of worm in faecal examination after 4 days of treatment[@bb0600]Unknown8--10 mg/kg per 2 weeksReported as effective without supporting data[@bb0310]Mebendazole[a](#tf0030){ref-type="table-fn"}Unknown3.2--6.4 mg/kgReported as effective without supporting data[@bb0310]Methylimidazole compoundUnknownUnknownReported as effective without supporting data[@bb0625]Milbemycin[a](#tf0030){ref-type="table-fn"}0.5 mg/kg, oncen/aCCRCGP (unpublished data)Ivermectin[a](#tf0030){ref-type="table-fn"}Usually oral0.2 mg/kg per day, twiceNone reduction of egg counts in faecal flotation examination after 10--15 days of treatment (without negative control)[@bb0215]Pyrantel pamoate[a](#tf0030){ref-type="table-fn"}Oral10 mg/kg per day, twice80.0% (ointment) reduction of egg counts in faecal floatation examination after 10--15 days of treatment[@bb0215]Piperazine citrateOral150 mg/kg, onceSignificant reduction of worms in faecal examination after 5 days of treatment[@bb0600]Unknown140--160 mg/kg per 2 weeksReported as effective without supporting data[@bb0310]Selamectin[a](#tf0030){ref-type="table-fn"}Spot-on6--12 mg/kg, oncen/aCCRCGP (unpublished data)TrichlorfonUnknown55 mg/kgNegative of worm in faecal examination after 5 days of treatment; significant side effect was observed[@bb0600][^6][^7][^8]

Due to the relatively short activity of anthelmintics in the host and the spread of large numbers of resilient *B. schroederi* eggs from infected animals in the environment, reinfection can occur rapidly (usually within 20--40 days; CCRCGP, unpublished records). Given that resistance to anthelmintics is increasing in a number of nematode species of both animals and humans (e.g. [@bb0130]; [@bb0435]), it is readily possible that resistance could develop in *Baylisascaris* as anthelmintics are routinely (excessively) administered to giant pandas at varying or imperfect dosages. Given the implementation of reintroduction programmes for captive giant pandas to the wild in recent years ([@bb0355]), drug resistance genes carried by *Baylisascaris* in released giant pandas could spread to and through wild populations.

Therefore, the possibility or likelihood that drug resistance in *Baylisascaris* could emerge as a problem has stimulated the search for alternative methods of prevention and control. One possibility could be to develop a vaccine against baylisascariasis. Inspired by research towards developing a vaccine against *A. suum* (see [@bb0120]; [@bb0265]; [@bb0405], [@bb0410], [@bb0415], [@bb0420]), considerable attention and research effort have been directed towards a recombinant subunit vaccine against baylisascariasis. It is encouraging to know that pigs can mount some protection (58%) following vaccination with recombinant antigens against challenge infection in a pig-*Ascaris* model ([@bb0420]), suggesting that vaccination against *B. schroederi* might be feasible. The first vaccination trial of a recombinant antigen, Bs-Ag3 (37 kDa), against *B. schroederi* infection in laboratory mice was reported in 2008 ([@bb0475]). Repeated subcutaneous administration (three times at 2-weekly intervals) of recombinant Bs-Ag3 with adjuvant in mice (BALB/c) resulted in a 63% reduction in the number of larvae collected from the lungs and a significant increase in total IgG in serum, in comparison with nonimmunised control mice. Subsequently, similar results were observed when mice were immunised with other recombinant antigens, Bs-Ag1 (64% reduction in number of lung larvae) and Bs-Ag2 (69% reduction), using same experimental design ([@bb0090], [@bb0095]). However, to date, there has been no investigation of the IgG subclasses in the sera from immunised mice or of the precise mechanism(s) by which protection is achieved against *B. schroederi.*

More recently, aside from these immunogens, more attention has focused on targets that play essential roles in the survival of the parasite. For example, [@bb0535] identified PYP-1, a new homologue of inorganic pyrophosphatases (PPases) ([@bb0125]), which likely plays critical roles in nematode development and moulting ([@bb0115]; [@bb0145]) and is distributed widely in the body wall, gut epithelium, ovary and uterus of adult female *Baylisascaris*. Two separate vaccination experiments in mice (BALB/c) showed that recombinant PYP-1 induced 69%--71% reductions in the number of liver-stage and lung-stage larvae 7 days following challenge infection ([@bb0535]). An investigation of the IgG subclasses in the sera of immunised mice showed that the level of IgG1 was significantly higher than IgG2a, with increased levels of IL-4 and IL-10, indicating a type 2 protective immune response ([@bb0535]).

Apart from work directed towards a vaccine against *B. schroederi*, efforts have also been made to understand aspects of the molecular biology and genetics of this parasite. In another study ([@bb0655]), the microRNA profile of *B. schroederi* via high-throughput sequencing and real-time quantitative PCR suggested that chitinases, ovarian or egg development related proteins and ribosomes were the targets of large numbers of microRNAs for the regulation of genes at the posttranscriptional level. This study also highlighted the potential of (at least some of) these microRNAs as intervention targets against baylisascariasis ([@bb0655]).

#### 2.1.1.6. Genetics {#s0055}

Following the publication of the complete mitochondrial genome of *B. schroederi* (see [@bb0530]), [@bb0205] undertook the first molecular characterisation of this parasite using nuclear ribosomal (r)RNA genes (18S and 28S) and a mitochondrial gene (12S) ([@bb0205]). Importantly, [@bb0205] showed that 18S was not a suitable candidate marker for assessing variation within the genus *Baylisascaris*, but that 28S and 12S sequences were capable of distinguishing *B. schroederi* from *B. ailuri* and *B. transfuga*.

Current and published phylogenetic trees for members of the genus *Baylisascaris* using 28S and mitochondrial *cox*1 gene data sets ([@bb0395]) consistently show two main groupings: one containing *B. schroederi*, *B. ailuri* from the red panda and *B. transfuga* from a variety of bear hosts, and the other comprising *Baylisascaris* species from raccoon, skunk and the South American kinkajou (see [Table 3](#t0020){ref-type="table"}). An analysis using recent sequence data (accession no. [KY465564](ncbi-n:KY465564){#ir0010}) places *B. devosi* from mustelids with *B. potosis* from this kinkajou ([Fig. 3](#f0020){ref-type="fig"} ). Additionally, a new species of *Baylisascaris*, called *B. venezuelensis*, from the South American spectacled bear (which is closely related to the giant panda; [@bb0380]) was described recently ([@bb0300]). Clearly, further sequence data from other members of the genus *Baylisascaris* are needed to gain a better understanding of the phylogeographic history of *B. schroederi*, which likely involves 'host-switching\' and 'ecological fitting\' ([@bb0010]).Fig. 3A phylogenetic tree showing the position of *Baylisascaris schroederi* in relation to all other species of *Baylisascaris* for which nucleotide sequence data are available, using *Ascaris lumbricoides* (from human) and *Toxascaris leonina* as outgroups. This tree is based on the analysis of 28S rRNA gene sequence data using the neighbour joining method. All data were obtained from the GenBank database, and accession numbers precede species names in the phylogenetic tree.Fig. 3Adapted from fig. 3A from Tokiwa, T., Nakamura, S., Taira, K., Une, Y., 2014. Baylisascaris potosis n. sp., a new ascarid nematode isolated from captive kinkajou, Potos flavus, from the Cooperative Republic of Guyana. Parasitol. Int. 63, 591--596.

Based on a morphological study by [@bb0445], giant pandas from the Qinling mountain range represent a distinct subspecies (*Ailuropoda melanoleuca qinlingensis*) from *Ailuropoda melanoleuca melanoleuca* and are thought to be genetically distinct from all other populations of pandas ([@bb0500]). Although the draft nuclear genome of the giant panda has been published ([@bb0200]), there is no study describing the use of large nuclear genomic sequence data sets to explore the population genetics of this panda. Several studies (see later) have attempted to search for genetic differences between *B. schroederi* of the two subspecies of giant panda. However, no genetic variation has been found between worms of the two subspecies of giant panda using first and second internal transcribed spacers (ITS-1 and ITS-2 = ITS) of nuclear ribosomal DNA ([@bb0220]; [@bb0650]). Other studies attempted to resolve the same issue using various mitochondrial gene markers. First, [@bb0675] used the *cyt*b gene and concluded that there was a high rate of gene flow among three populations of *B. schroederi* representing the two recognised subspecies. Second, [@bb0540], [@bb0550] used portions of the mitochondrial *cox*1, *atp*6 and 12S rRNA genes, which displayed very few parsimony informative sites. Again, these authors found no discernable genetic difference in worms among the populations from distinct habitats of the giant panda (i.e. the Minshan, Qionglai and Qinling mountain ranges). A low level of genetic diversity but a high level of gene flow in worms suggested the potential for a rapid spread of drug resistance in *B. schroederi* (see [@bb0540]). Third, [@bb0660] did not find support for the genetic substructuring within *B. schroederi* among samples from the Qinling mountains and one sample from Sichuan province using portions of the mitochondrial genes *cyt*b, *cox*3 and *nad*5. Unfortunately, to date, only mitochondrial genes, whose validity as a population genetic markers has been questioned ([@bb0065]), have been used to explore structuring and substructuring in *B. schroederi* populations. Therefore, future studies should be conducted using multiple neutral nuclear genomic markers. A project in China is now underway to sequence, assemble and annotate the nuclear genome of *B. schroederi*, which, if successful, would underpin such a focus.

### 2.1.2. Chorioptes panda {#s0060}

*Chorioptes* spp. (Acariformes: Psoroptidae) are skin mites that cause mange in domestic and wild animals. These mites are commonly found in herbivorous hosts, including cattle, sheep, goats, horses, camelids and moose ([@bb0605]). *Chorioptes* was first found in the ears of captive giant pandas in the Paris Zoo, France and named *Chorioptes panda* ([@bb0055]), and subsequently reported in China in 1986 ([@bb0590]). However, *C. panda* was considered an invalid species by some researchers ([@bb0615]). In ensuing years, other researchers reappraised the morphology of the mite, undertook phylogenetic analyses of mitochondrial *cox*1 and nuclear 18S rRNA gene data sets, and concluded that *C. panda* is a valid species ([@bb0020]; [@bb0100]; [@bb0480]).

Although no epidemiological data are available, *C. panda* is commonly found in captive populations of the giant panda ([@bb0325]; [@bb0450]; [@bb0560]; [@bb0580]; [@bb0670]), particularly in late spring and early autumn (CCRCGP, unpublished records). However, to date, there is only one published record of *C. panda* infection in wild populations of the giant panda ([@bb0480]), although obtaining such information for such populations is a considerable challenge. In addition, wild giant pandas are usually solitary animals, and only occasionally interact with each other, mainly during their short mating season ([@bb0350]). Thus, the probability of direct cross-transmission of this mite appears to be low.

Typically, *C. panda* is found on the eyelids, lips and ears of giant pandas ([Fig. 2](#f0015){ref-type="fig"}), causing mild alopecia, erythema and crusting, and affecting the sleep and appetite of giant pandas ([@bb0325]). The control of *Chorioptes* mange relies mainly on chemotherapeutic treatment. Macrocyclic lactones (e.g. ivermectin and selamectin) have been found to be effective when routinely administered on a monthly basis (CCRCGP, unpublished records). Closantel ([@bb0450]) and deltamethrin ([@bb0560]) have also been proposed to be effective against *C. panda* (see [@bb0450]; [@bb0560]), but well-controlled experiments are needed to verify the authors' claims.

### 2.1.3. Ixodidae (Hard Ticks) {#s0065}

Other ectoparasites that can affect the health of the giant panda are (blood-feeding) hard ticks. Since the first description of tick infection by *Haemaphysalis warburtoni* ([@bb0510]), an increasing number of hard tick species have been identified on giant pandas in the last two decades ([@bb0155]; [@bb0240]; [@bb0320]; [@bb0610]). To date, 13 species representing 3 genera of hard ticks have been proposed as recorded (from rescued, sheltered or dead, wild giant pandas). These ticks include members of the genera *Haemaphysalis* (9 species), *Ixodes* (3 species) and *Dermacentor* (1 species) ([Table 2](#t0015){ref-type="table"}). Of these ticks, *Haemaphysalis flava* has been most commonly reported in giant panda populations ([@bb0030]; [@bb0240]; [@bb0320]). Recently, molecular tools have also been employed for the genetic characterisation of ticks from the giant panda. Using mitochondrial and ribosomal DNA markers as well as key morphological characters, *H. flava* was identified to predominate on giant pandas in the Qinling mountain range ([@bb0030]). Although there is no report on mortality caused by such hard ticks, morbidity involving dermatitis and/or weight loss has been recorded in infested giant pandas (CCRCGP, unpublished records). Similar to the treatment of *C. panda*, ivermectin and selamectin are the compounds most commonly used against ticks in breeding centres and zoos (CCRCGP, unpublished clinical records). To date, there are no reports of any associated tick-borne diseases in the giant panda.

2.2. Protists: An Emerging Issue? {#s0070}
---------------------------------

Using molecular diagnostic tools, such as PCR, *Cryptosporidium* spp. ([@bb0230]; [@bb0495]), *Enterocytozoon bieneusi* (see [@bb0390]) and *Toxoplasma gondii* (see [@bb0245]) have been detected and characterised from giant pandas. During a routine coprological examination (flotation) of 57 faecal samples at CCRCGP ([@bb0230]), one sample from an 18-year-old male captive giant panda was test-positive for *Cryptosporidium*, with oocysts being 4--4.6 μm in size. A phylogenetic analysis of partial 18S rRNA (786 bp), 70 kDa heat shock protein (1879 bp) and actin (1044 bp) gene sequence data (GenBank accession nos. [JF970610](ncbi-n:JF970610){#ir0015}, [JN588571](ncbi-n:JN588571){#ir0020} and [JN969985](ncbi-n:JN969985){#ir0025}) showed that *Cryptosporidium* from the giant panda is genetically similar to that of genotype of *Cryptosporidium* from a black bear (*Ursus americanus*) (98%--99.5%; GenBank accession nos. [AF247535](ncbi-n:AF247535){#ir0030}, [AF247536](ncbi-n:AF247536){#ir0035} and [AF382339](ncbi-n:AF382339){#ir0040}). Due to its sequence divergence (0.5%--2.0%) from other nucleotide sequences available in the GenBank database, the *Cryptosporidium* taxon from the giant panda was inferred to be a novel genotype, designated *Cryptosporidium* 'giant panda genotype' ([@bb0230]). Subsequently, a study of a larger sample size (*n*  = 322) confirmed the presence of *Cryptosporidium* infection in captive and wild giant panda populations, recording prevalences of 15.6% (19/122) and 0.5% (1/200), respectively ([@bb0495]). Interestingly, a genetic analysis of partial 18S rRNA gene sequence data revealed that *Cryptosporidium* from these pandas was more similar genetically (94.1%--99.8%) to *C. andersoni* from cattle than to the *Cryptosporidium* 'giant panda genotype\' (84.6%--89.8% similarity) ([@bb0230]), even though most test-positive samples (*n*  = 17) were collected from the same conservation centre (i.e. CCRCGP). This finding raises a question about the spectrum of *Cryptosporidium* genotypes that might infect the giant panda in different environments, geographical localities and times of the year. However, the authors ([@bb0495]) suggested that seasonal variation in the distribution of *Cryptosporidium* might be a possible reason for this finding. In addition, these authors reported a higher prevalence of *Cryptosporidium* infection in captive than in wild giant panda populations. Whether this difference relates to a high degree of transmission of *Cryptosporidium* among giant pandas or between other animals and pandas in a captive (high population density) environment remains to be elucidated. Although no clinical signs, such as diarrhoea (often associated with cryptosporidiosis), were observed in either of these two studies ([@bb0230]; [@bb0495]), systematic investigations should be performed to gain a better understanding of the pathogenicity/virulence of *Cryptosporidium* in the giant panda as a basis for improved prevention or control in the event of clinical outbreaks.

Recently, *E. bieneusi* was identified in captive giant pandas in Shanxi province, with an estimated prevalence of 9% (4/46) ([@bb0390]). Subsequent phylogenetic analysis based on the nuclear ITS rDNA sequences of *E. bieneusi* suggested that a novel genotype I-like *E. bieneusi* occurs in giant pandas. Although *E. bieneusi* is known as an emerging and opportunistic enteric pathogen, causing diarrhoea in humans and animals, and progress has been made in our knowledge of the epidemiology of *E. bieneusi*, the transmission routes of this pathogen are still unclear ([@bb0260]; [@bb0340]). Given the possibility of transmission via respiratory secretions ([@bb0255]) and the potentially broad host range of this pathogen ([@bb0345]), whether this new genotype I-like *E. bieneusi* has a specific host affiliation to the giant panda remains to be explored. Similar to the reports of *Cryptosporidium* infection in giant pandas, no associated clinical signs were observed in *E. bieneusi*-infected animals ([@bb0390]).

Meanwhile, other than asymptomatic *Cryptosporidium* and *Enterocytozoon* infections in giant pandas, there is one report of an acute, fatal toxoplasmosis case, characterised by serious respiratory and gastroenteritis symptoms ([@bb0245]). Here, a 7-year-old giant panda was found dead at Zhengzhou Zoo, China ([@bb0245]). The necropsy findings, and serological results from an immunofluorescence assay and a modified agglutination test as well as PCR results for DNA from tissue biopsy samples (from liver, spleen, lungs, kidneys and intestines) all indicated that the giant panda had died from acute toxoplasmosis. Additional multilocus, nested PCR--RFLP analysis, using 10 genetic markers (*SAG*1, *SAG*2, *SAG*3, *BTYB*, *GRA*6, *c*22-8, *c*29-2, *L*358, *PK*1 and *Apico*; see [@bb0050]), provided evidence that the *T. gondii* isolate causing this panda\'s death represented an atypical genotype (with reference to strains GT1, PTG, CTG, MAS, TgCgCal, TgCatBr5, TaCatBr40, TgCatBr64 and TgRsCr1). The findings suggested that a *T. gondii*-infected stray cat or rodents in the zoo might have been the source of infection in this fatal case ([@bb0245]).

3. Conclusions and a Perspective on Future Research {#s0075}
===================================================

This chapter has reviewed current information on parasites of the giant panda, but it seems that we have only just 'scratched the surface' when it comes to research of the giant panda. Therefore, in our opinion, there is a need to conduct research in the following areas: (1) detailed genetic comparison of the two subspecies of giant panda using advanced genomic sequencing and analytical approaches employing the genomic resources available for the panda (cf. [@bb0200]); (2) more morphological and molecular studies of parasites of the giant panda, improved (genetic) classification of known taxa, as well as detailed molecular epidemiological studies to assess the prevalence and distribution of parasites in captive and wild populations; (3) identification and characterisation of any emerging parasites and other pathogens using noninvasive sampling and PCR-based molecular or next-generation sequencing tools (cf. [@bb0150]); (4) studies to improve our understanding of the fundamental biology and molecular biology of *B. schroederi*; (5) investigations to assess whether anthelmintic resistance is emerging in *B. schroederi* and whether it is spread in the field and (6) work towards improved methods for the prevention or control of baylisascariasis (e.g. vaccination).

Without an accurate catalogue of which parasite species exist in wildlife, and a deep understanding of their life cycles, biology and the diseases that they cause, it is challenging to evaluate their risk to animal health ([@bb0045]). Although numerous parasite taxa (*n*  = 29) have been detected/recorded in the giant panda ([Table 2](#t0015){ref-type="table"}), many of them, such as *Sarcocystis*, *Strongyloides* and lungworm (see [Table 2](#t0015){ref-type="table"}), have not been described in any detail, and, to our knowledge, no voucher specimens are readily accessible in China. In our opinion, it should be a priority to classify known parasite taxa using international taxonomic rules. In addition, studies are needed to understand the biology and the epidemiology of these parasites, to guide conservation decisions.

Previous observations of *B. schroederi* infection in baby giant pandas (\< 2 months) indicate the possibility of transplacental transmission ([@bb0570]), but there is no direct evidence of this mode. Thus, it would be interesting to undertake studies to critically assess whether *B. schroederi* can undergo transplacental and/or transmammary transmission. In addition, a major impediment to large-scale epidemiological investigations of giant panda parasites is the difficulty of assessing infection status in free-ranging populations. This limitation seems to have been somewhat overcome by the development of a PCR-based diagnostic approach (see [Section 2.1.1.4](#s0045){ref-type="sec"}; [@bb0485]) for the simultaneous genetic 'fingerprinting' of individual pandas (see [Section 2.1.1.2](#s0035){ref-type="sec"}; [@bb0635]) and the detection of their parasites in faecal samples, which could be used for field studies, in order to explore the distribution and dynamics of parasitic infections/diseases. Moreover, it would not be surprising to detect new parasite species using PCR-based or high-throughput DNA sequencing technology, considering the recent detection of new genotypes of protists (i.e. *Cryptosporidium*, *Enterocytozoon* and *Toxoplasma*) in the giant panda ([@bb0230]; [@bb0245]; [@bb0390]; [@bb0495]), which could not be characterised using conventional parasitological methods.

There is no doubt that baylisascariasis continues to cause serious health problems in the giant panda and will likely remain one of the biggest challenges for the conservation of this animal. Although modern anthelmintics appear to be reasonably effective for the treatment of baylisascariasis, the dissemination of large numbers of eggs into the environment and the resilience of these thick-shelled eggs make this disease/infection challenging to control *B. schroederi* without the implementation of an integrated approach, including management components (pen cleaning protocols and housing infrastructure) and regular monitoring for infection in different age groups of panda. Because of the potential for anthelmintic resistance to develop in *B. schroederi*, as a consequence of routine and excessive use of anthelmintics in captive animals, an integrated approach for baylisascariasis control needs to be explored. Such approaches might include the use of effective disinfectants (against the egg stage) to block transmission, new drugs with different modes of action and/or vaccination. Early work showed that the disinfectant neopredisan (active constituent: chlorocresol or *p*-chloro-*m*-cresol) has a high efficacy (100%) against *A. suum* eggs under laboratory conditions ([@bb0285]). Whether this chemical has similar efficacy against *B. schroederi* eggs remains to be determined.

On the other hand, lessons learned from previous attempts to develop vaccines against ascaridoid nematodes ([@bb0265]; [@bb0420]) indicate that it is critical to gain knowledge of the immunobiology of the parasite and to ensure that any vaccine candidate consistently induces high-level and long-lasting protective immunity ([@bb0075]). Also, a deep knowledge of parasite-derived molecules involved in vital developmental processes in *Baylisascaris*, host--parasite interactions and mechanism by which this nematode develops and survives within the host might assist in defining novel candidate vaccine targets. Clearly, developing an anti-*Baylisascaris* vaccine for an endangered animal, such as the giant panda, presents considerable challenges, such that immunogens might need to be selected based on consistent protection and immunorecognition in different laboratory (paratenic) hosts (e.g. mice, rodents and/or rabbits) prior to any well-controlled trials (without experimental challenge infection) in captive panda populations in which *B. schroederi* is known to be highly endemic, to assess whether a reduction in prevalence and intensity of infection is achievable.

In the last three decades, multidrug resistance has emerged across five continents in endoparasites and ectoparasites of animals and, to some extent, those of humans ([@bb0015]; [@bb0035]; [@bb0070]; [@bb0130]; [@bb0280]; [@bb0370]; [@bb0435]). Given that anthelmintics are often used routinely and excessively in a suppressive manner in captive animal populations, there is a probability that drug resistance is emerging (cf. [@bb0070]). If this is the case for *B. schroederi*, what are the implications of this when captive animals are released into the wild? In the first instance, it seems pertinent to assess *B. schroederi* for resistance to commonly used anthelmintics using a faecal egg count reduction testing (FECRT) protocol similar to that recommended by the World Association for the Advancement of Veterinary Parasitology (WAAVP) for livestock animals ([@bb0040]). The presence of anthelmintic resistance in *B. schroederi* would make immunoprevention via vaccination even more attractive.

Apart from addressing some of these issues, there is an opportunity to pool expertise from a range of key experts in parasitology, in order to address some of the salient parasite problems and management issues to ensure that the health of captive giant pandas is maximised. By sharing new knowledge and information, this would not only significantly increase the utilisation of available data and clinical information but also enhance research opportunities to ensure the conservation of the giant panda. Although this animal is critically endangered, this review indicates, surprisingly, that parasitological research of this animal is in its infancy. Thus, much can be done to contribute towards the conservation of this iconic species. Although major public and scientific attention has focused on the conservation of the giant panda, with injections of funding from a number of bodies including the Giant Panda Conservation Foundation, it seems that very little funding is spent on the research of infectious (including parasitic) diseases of this species. Therefore, we strongly recommend that more attention be paid to the diseases that are likely to threaten this animal\'s conservation. We strongly believe that there is little room for error at this time point in history.
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[^1]: n/a, no information available.

[^2]: Adapted from Kazacos, K.R., 2008. *Baylisascaris procyonis* and related species. In: Samuel, W.M., Margo, J.P., Kocan A.A. (Eds.), Parasitic of Wild Mammals. Iowa State University Press, Ames, USA, pp. 301--341.

[^3]: List of definitive hosts is not extensive due to the numerous species recorded; see [@bb0365] and [@bb0140] for extensive list.

[^4]: *CCRCGP*, China Conservation and Research Centre for the Giant Panda; *CRBGP*, Chengdu Research Base of Giant Panda.

[^5]: *12S rRNA*, mitochondrial 12S ribosomal RNA gene; *cox*2, mitochondrial cytochrome *c* oxidase subunit 2 gene; n/a, not available; *PCR/CE-SSCP*, PCR-based capillary electrophoretic single-strand conformation polymorphism analysis.

[^6]: Anthelmintics used in practice currently.

[^7]: None of these studies followed International Harmonisation of Anthelmintic Efficacy Guidelines ([@bb0425], [@bb0430]); n/a, not available.

[^8]: *CCRCGP*, China Conservation and Research Centre for the Giant Panda; *CRBGP*, Chengdu Research Base of Giant Panda.
